Notably, while butyrate supplementation ameliorated colitis severity in FDD mice, it did not significantly alter plasma GLP-1 levels compared to unsupplemented FDD controls, likely reflecting its broader mucosal-protective effects that reduced the pathological drive for GLP-1 secretion (fig. Here, GCG is linked to colitis.